Evolution is at the core of the impending antibiotic crisis. Sustainable therapy must thus 25 account for the adaptive potential of pathogens. One option is to exploit evolutionary trade-26 offs, like collateral sensitivity, where evolved resistance to one antibiotic causes 27 hypersensitivity to another one. To date, the evolutionary stability and thus clinical utility of 28 this trade-off is unclear. We performed a critical experimental test on this key requirement, 29
Imamovic & Sommer, 2013). One promising strategy is based on evolved collateral 44 sensitivity: the evolution of resistance against one drug A concomitantly causes 45 hypersensitivity (i.e., collateral sensitivity) to a second drug B (Szybalski & Bryson, 1952) . If 46 evolved collateral sensitivity is reciprocal, it can -in theory -trap the bacteria in a double 47 bind, thereby preventing the emergence of multi-drug resistance during treatment (Baym, 48 Stone, & Kishony, 2016; Pál, Papp, & Lázár, 2015; Roemhild & Schulenburg, 2019) . Recent 49
large-scale studies have demonstrated that evolved collateral sensitivity is pervasive in 50 laboratory strains and clinical isolates of distinct bacterial species (Barbosa et al., 2017a;  recent studies, both with different main research objectives, yielded some insight into this 86 topic. One example was focused on historical contingency during antibiotic resistance 87 evolution of P. aeruginosa (Yen & Papin, 2017) . As part of the results, the authors identified 88 lineages with evolved resistance against ciprofloxacin that simultaneously showed increased 89 sensitivity to piperacillin and tobramycin. The reverse pattern (i.e., evolved high resistance 90
to either piperacillin or tobramycin and increased sensitivity to ciprofloxacin) was not 91
observed and, thus, this case represents an example of uni-directional collateral sensitivity. 92
The subsequent exposure of the ciprofloxacin-resistance lineages to either piperacillin or 93 tobramycin led to the evolution of resistance against these two antibiotics and substantial 94
(yet not complete) re-sensitization to ciprofloxacin. The second study focused on evolving E. 95
coli populations in a morbidostat, in which the bacteria were exposed to repeated switches 96 between two drugs (Yoshida et al., 2017) . The evolution of multi-drug resistance was only 97
prevented in the two treatments with polymyxin B that were also characterized by evolved 98 collateral sensitivity, although again only in one direction (Yoshida et al., 2017) . To date, the 99 general relevance of this third factor is still unclear, especially for conditions when collateral 100 sensitivity is reciprocal and when the evolving populations are also allowed to go extinct 101 (i.e., they cannot overcome the evolutionary trade-off). 102 103
Here, we specifically tested the potential of the model pathogen P. aeruginosa to escape 104 reciprocal collateral sensitivity through de novo evolution. We focused on the first switch 105 between two drugs, because the evolutionary dynamics after this first switch will reveal the 106 ability of the bacteria to adapt to the second drug, against which they evolved sensitivity, 107
and, if so, whether this causes re-sensitization to the first drug. These two aspects are key 108 criteria for applicability of a treatment strategy that exploits evolved collateral sensitivities. 109
Our analysis is based on a two-step evolution experiment. Bacteria first evolved resistance 110 against a first drug A and concomitant sensitivity against a second drug B. Thereafter, 111
bacteria were subjected to a second evolution experiment, during which they were allowed 112 to adapt to the second drug B, either alone or additionally in the presence of the first drug A. 113
Phenotypic characterization of the evolved bacteria was combined with genomic and 114 functional genetic analyses, in order to determine the exact targets of selection under these 115 conditions. 116 starting at IC 50 (dashed black lines) and ending at levels above the IC 95 of the collaterally sensitive clone (mild 155 increases, dashed orange line), or that of the PA14 wildtype strain (strong increases, dashed black lines; 156 detailed information on concentrations in Supplementary Table 1) 
162 163
Extinction rates were high even under mild selection regimes.
164
The imposed antibiotic selection frequently caused population extinction ( Fig. 2 
-Source 165
Data 2), even though sublethal drug concentrations were used. Extinction events occurred 166 significantly more often when selection for the original resistance was maintained by the 167 presence of both drugs (extinction in constrained treatments vs. only one drug, χ 2 =12.9, 168 df=1, P<0.0001; Fig. 2 ). In treatments with only the second drug B, extinction occurred 169 significantly more often under strong, but not mild concentration increases (strong vs. mild 170 increases in unconstrained environments, χ 2 =5.5, df=1, P=0.019). Drug switches with the 171 antibiotic pair STR/PIT was particularly successful, with 33 extinction events (~51%, Fig. 2 ).
172
The results differed for the CAR/GEN pair, which produced only 7 extinctions (~10%), all 173 restricted to one drug order, GEN->CAR, suggesting asymmetry in the ability to counter 174 collateral sensitivity. From this, we conclude that strong genetic constraints against an 175 evolutionary response to collateral sensitivity caused frequent population extinctions for 176 STR/PIT switches, whereas evolutionary rescue was possible for the GEN/CAR pair, although 177 influenced by drug identity and order. Novel resistance evolved rapidly in many of the surviving populations. 187 We subsequently focused our analysis of the evolutionary dynamics on the surviving 188 populations of the CAR/GEN pair and identified rapid adaptive responses, especially when 189 not constrained by the presence of the two drugs ( Fig. 3 ). This analysis was not possible for 190
the STR/PIT pair, because few populations survived treatment. For the CAR/GEN pair, we 191 measured bacterial adaptation using relative biomass (see methods and Roemhild et al., 192 2018) and found it to have increased in all surviving populations ( Fig. 3a and b -Source Data 193
3). For both drug orders, the increase was significantly slower in the constrained treatments, 194
and, to a lesser extent, for the strong concentration increases ( Fig. 3a and b, Supplementary 195 Table 2 ). In consistency with the asymmetry in extinction, the CAR->GEN switch (with no 196 extinction) maintained a high relative biomass across time, while the reverse direction GEN-197 >CAR (with extinction) produced lower relative biomass levels. These results indicate that P. 198 aeruginosa can evolve resistance against a drug, to which it had previously shown 199 hypersensitivity, and that such evolutionary rescue is favored for the suboptimal switch. We Drug order determined re-sensitization or emergence of multidrug resistance.
223
Adaptation in the surviving populations of the CAR/GEN pair caused multidrug resistance in 224 the suboptimal switch, but re-sensitization to similar levels than the PA14 ancestor 225
( Supplementary Fig. 1 -Source Data 4 and 5) in the alternative switch ( Fig. 3c and d -Source 226
Data 6). In detail, all surviving populations significantly increased resistance against the 227 second drug ( Fig. 3c and d ; Supplementary Table 3 ) -in agreement with the recorded 228 biomass dynamics. In the suboptimal switch, CAR->GEN, all populations maintained their 229 original resistance, thereby yielding bacteria with multidrug resistance. This was different for 230 the alternative direction GEN->CAR, where the original resistance was only maintained when 231 both drugs were present in combination (constrained environments). Only under 232 unconstrained evolution, we observed cases of significant re-sensitization to the first drug. 233
We conclude that drug order can determine treatment efficacy, enhance or minimize 234 multidrug resistance, and, in specific cases, lead to a re-sensitization towards the first drug in 235 the surviving populations, as required for applicability of collateral sensitivity cycling 236 (Imamovic & Sommer, 2013) . 237 238
We hypothesized that the contrasting evolutionary outcomes in constrained versus 239 unconstrained treatments of the GEN->CAR switch were caused by an additional trade-off, in 240 this case between drug resistance and growth rate. The starting clones for the second 241 evolution experiment had significantly impaired growth rate and final yield under drug-free 242 conditions, with respectively ~25-50% and 10-50% reductions in fitness relative to the 243 ancestor (Barbosa et al., 2017). As a consequence, selection may have favored variants with 244 higher growth rates. For this particular switch, we indeed found increased growth relative to 245 the resistant ancestral clone for all treatments. The growth rate increases were significantly 246 larger in lineages from unconstrained than constrained treatments ( Fig. 3f -Source Data 7, 247 Supplementary Fig. 2 -Source Data 7). In this case, resistance levels also increased slightly 248
(but not significantly) for the unconstrained compared to the constrained treatments 249
( Supplementary Table 4 ). Similar variations were not observed for the alternative switch 250 CAR->GEN ( Fig. 3e -Source Data 7, Supplementary Fig. 2 , Supplementary Table 4 ). We 251
conclude that re-sensitization was favored over multidrug resistance in the GEN->CAR 252 unconstrained treatments, because it provided the advantage of increases in growth rate 253 and, to a lesser extent, resistance to the new drug. This data suggests that fitness costs can 254 determine treatment outcome upon collateral sensitivity switches. 255 256
Whole genome sequencing identified possible targets of antibiotic selection. 257 We used population genomic analysis to characterize specific functional changes that were 258 likely targeted by antibiotic selection and allowed populations to survive the second 259 evolution experiment for the CAR/GEN pair ( Fig Thus, re-sensitization to GEN may be caused by antagonistic pleiotropy of nalC mutations 282 that override the resistance of the original pmrB mutation (Source Data 8). In addition, there 283 may be epistasis between the two functional modules. A complementary mechanism for re-284 sensitization against GEN is the re-mutation of pmrB (Source Data 8). In three cases nalC 285 mutations coincided with mutations in pmrB, including two deletions of 17 and 225 base 286 pairs. Whilst the original SNP in pmrB altered gene function, the latter deletions may have 287 suppressed the expression of the original SNP by pseudogenizing the gene. We conclude that 288 mutations in the nalC or nalD regulators of the MexAB-OprM pump, sometimes in 289 combination with follow up mutations in pmrB are likely to account for the re-sensitization 290 towards the first drug GEN. 291 292 
303 304
Functional genetic analysis revealed asymmetric epistasis among adaptive mutations. 305 We next investigated whether epistasis between the two functional modules of efflux 306 regulation (MexAB-OprM regulation by nalC or nalD) and surface charge modification (pmrB) 307
may have contributed to re-sensitization using functional genetic analysis. The respective 308 single and double mutations were re-constructed in the common ancestral background of 309 PA14 (see methods for the specific mutations) and changes in resistance against CAR and 310 GEN were measured using fold change of minimal inhibitory concentrations (MIC, Fig. 4c and 311
d -Source Data 9). On CAR, the pmrB mutant had half of the MIC of PA14 (confirming 312 collateral sensitivity), whilst nalC and nalD mutants had increased resistance to CAR. The 313
double mutants had lower MIC on CAR than the nalC and nalD single mutants (Fig. 4c ). The 314 extent of MIC changes in the double mutants corresponded to the product of the individual 315 effects in the respective single mutants, thus indicating an additive interaction among 316 mutations on CAR. On GEN, however, the double mutants had substantially lower MICs than 317 expected from the single mutants ( Fig. 4d ), strongly suggesting negative epistasis. In detail, 318
GEN-resistance relative to PA14 was 0.4x for nalC (collateral sensitivity), 1x for nalD, and 57x 319
for pmrB (Fig. 4d ). The pmrB, nalD double mutant had 3x lower MIC to GEN than expected 320 from the individual effects. The pmrB, nalC double mutant had >30x lower MIC to GEN than 321 expected from the individual effects, resulting in greater sensitivity than PA14 (Fig. 4d ). 322
Altogether, we conclude that re-sensitization to GEN is mediated by antagonistic pleiotropy 323
and negative epistasis. 324 325 326
Discussion

328
Collateral sensitivity is a pervasive feature of resistance evolution, but its potential for 329 medical application is currently debated (Nichol et evolutionarily stable and cannot be easily overcome. As a consequence, it should either drive 332 bacterial populations to extinction or minimize the emergence of multi-drug resistance by 333
re-sensitization to one of the antibiotics. We here tested the validity of these key 334
assumptions with the help of evolution experiments and the model pathogen P. aeruginosa. 335 We found that the effective exploitation of evolved collateral sensitivity in sequential 336 therapy is contingent on drug order and combination, fitness costs, and also epistatic genetic 337
interactions ( Supplementary Fig. 3 ). 338 339
Evolved reciprocal collateral sensitivity generally limited bacterial adaptation. The effect was 340 strongest when the first antibiotic was maintained and a second was added, as reflected by 341 the elevated extinction rates in the constrained environments. This finding may point to a 342
promising, yet currently unexplored treatment strategy, namely single-drug therapy 343
followed by combination therapy, that can maximize exploitation of the evolutionary trade-344
off. Yet, extinction rates were even high under unconstrained conditions, when drugs were 345
replaced, and in spite of a relatively mild selection intensity, for example an increase in drug 346 concentration from IC 50 to IC 95 over a course of 12 days. We observed higher extinction and 347 slower growth improvements in strong, compared to mild drug increases. This finding is 348
generally consistent with previous studies, performed in different context, in which 349 narrowed mutation space upon fast environmental deterioration increased extinction should help us to refine our understanding of treatment efficacy. 359 360
In the treatments that replaced drugs, evolutionary stability of the resistance trade-off was 361 determined by drug order. Our results for the CAR/GEN pair suggest that this asymmetric 362 stability was determined by variation in either the extent of hypersensitivity and/or the 363 associated physiological fitness costs. The extent of hypersensitivity of the GEN-resistant 364 strain towards CAR was substantially larger than that of the reverse case (Fig. 1c) . A similar 365 difference was observed for fitness costs under antibiotic free conditions (see bacterial yield 366
in the no-drug environment on the far left in Fig. 1b and c) . It is indeed the GEN->CAR switch 367
(rather than the reciprocal CAR->GEN switch) that produced higher extinction levels (Fig. 2) , 368
lower adaptation rates ( Fig. 3a and b) , and a re-sensitization in the surviving populations 369 ( Fig. 3c and d) . We conclude that, if the degree of hypersensitivity and/or fitness costs is 370 large, it may be more difficult to counter the strong growth restriction in the presence of the 371 second drug within a limited time frame.
373
Drug re-sensitization in the unconstrained treatment of GEN->CAR was likely dependent on 374 negative epistasis among pleiotropic resistance mutations. In particular, we found that 375 mutations in pmrB and the efflux regulators nalC and nalD interacted negatively with each 376 other and caused a complete re-sensitization of bacteria that were previously resistant 377 against GEN. While re-sensitization reliably occurred for the GEN->CAR treatment, it did not 378 occur in the reverse case. Similar examples of antibiotic re-sensitization were previously 379
reported for E. coli and P. aeruginosa, but these relied on different mechanisms. For E. coli, 380
repeated alternation between two antibiotics led to re-sensitization as a consequence of 381 clonal interference between variants in two genes, secD and/or basB. thus possibly contributing to efficacy of treatment in our case. 396 397
We anticipate that the findings of our study could help to guide the design of sustainable 398
antibiotic therapy that controls the infection, whilst reducing the emergence of multidrug 399
resistance. The refined exploitation of collateral sensitivity represents a promising addition 400
to new evolution-informed treatment strategies, including as alternatives specific 401 combination treatments ( provided a detailed growth trajectory that accurately describes the dynamics of resistance 457 emergence. Relative biomass was defined as total optical growth relative to untreated 458 control treatments, and was calculated by the ratio of the areas under the time-OD curves of 459 treated compared to untreated controls that are passaged in parallel, as previously 460
described (Roemhild et al., 2018) . 461 462
Resistance of evolved populations. Resistance of evolved populations was measured for the 463 respective antibiotic pairs (GEN/CAR or STR/PIT), as described above, but using two-fold 464
concentrations (1/4 to 8x the MIC of the starting clone). The respective starting clones of 465 each evolved population served as controls and were measured in parallel. Resistance re-sensitization against GEN, we performed the experiments a second time including the 471 PA14 ancestor to serve as an additional control ( Supplementary Fig. 1 ).
473
Growth rate analyses. Maximum exponential growth rates of evolved and ancestral 474 populations were calculated from growth curves in drug-free media, using a sliding window 475 approach. For measurements, sample cultures were diluted 50x from early stationary phase 476
into 96-well plates (100 µl total volume) and growth was measured by OD 600 every 15 min 477
for 12 h. Growth rate were calculated from log-transformed OD data for sliding windows of 1 478 h, yielding two-peaked curves indicating initial growth on glucose and citrate. The reported 479
values the maximum values of the first, larger peak. The values reported in Fig. 3 are the 480 changes of growth rate in evolved populations relative to their resistant ancestors. 481 482
Genomics. We re-sequenced whole genomes of 5 starting clones (CAR-10 clone 2, GEN-2 483 clones 1-4), and 21 evolved populations (all descendants of these clones from plate B, 484
including 5 untreated evolved control populations and 16 populations adapted to different 485 treatment conditions) using samples from the end of the evolution experiments. Frozen 486 material was thawed and grown in 10 ml of M9 minimal medium for 16-20 h at 37˚C with 487 constant shaking. Genomic DNA was extracted using a modified CTAB buffer protocol 488 (Schulenburg et al., 2001) Epistasis analysis. Resistance of constructed mutant strains was measured in direct 519
comparison to wildtype PA14, as described above. Relative fold-changes in MIC were 520 calculated from dose-response curves. The expected relative resistance of the double 521 mutants was calculated by multiplication of the mutation's individual effects, as previously 522
described (Wong, 2017) . For example, if mutation A conferred a 2-fold increase in resistance 523
and mutation B conferred a 4-fold increase of resistance, the expected resistance of the 524 double mutant AB would be 2x4 = 8. A deviation from this null model indicates epistasis, 525
which can be either positive (greater resistance than expected) or negative (lesser resistance 526 than expected). 
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Source Data 1 (separate file) 776
Source data for Figure 1b a Separate GLMs were performed for each antibiotic used during experimental evolution with the cumulative relative growth of surviving populations as the response variable, and pace of drug concentration increase (strong or mild) and constraint (constrained or unconstrained) as explanatory fixed factors. Starting clonal population was considered as a nested random factor. We used a type-II Wald χ 2 -test to evaluate the effect of these variables. We used the false discovery rate to adjust the P values for multiple comparisons.
Source Data 1 (separate file)
Source data for Figure 1b and 1c. Mean optical density and CI95 values obtained after 12 hours of growth in minimal media and different antibiotics. The populations tested here include the PA14 wt, and four resistant populations described in Barbosa et al., 2017. Each value is the average of 8 technical replicates per bacterial population.
Source Data 2 (separate file)
Source data for Figure 2 . Count data of extinction events. Extinct populations were determined by their inability to grow in rich media after 24 hours of incubation at 37˚C.
Source Data 3 (separate file)
Source data for Figure 3a and 3b. Evolutionary dynamics summarized by the area under the curve (AUC) relative to the treatment with no drugs for the evolution experiments CAR R ->GEN and GEN R ->CAR.
Source Data 4 (separate file)
Source data for Supplementary Figure S1a . Growth characteristics measured by optical density under various drug concentrations for the populations adapted to unconstrained environments (strong and mild), as well as the PA14 wt against gentamicin. Each population-drug concentration was evaluated in triplicate.
Source Data 5 (separate file)
Source data for Supplementary Figure S1b . Change in resistance of populations adapted to unconstrained environments (strong and mild) relative to the PA14 wt against 10 gentamicin. This was inferred by calculating the difference between the evolved populations and the PA14 wt in the area under the curve across drug concentrations.
Source Data 6 (separate file)
Source Data for Figure 3c , 3d, 3e, and 3f. Dose-response curves data of surviving populations and the respective ancestors challenged with carbenicillin or gentamicin.
Optical density values were recorded after 12 hours of incubation at 37˚C.
Source Data 7 (separate file)
Source Data for Figure 3e , 3f, and Supplementary Figure S2 . Growth rate estimates of the surviving populations and the respective ancestors challenged with carbenicillin or gentamicin. Growth rate was calculated as indicated in the Methods section.
Data Source 8 (separate file)
Source Data for Figure 4a and 4b. Genetic changes compared to Pseudomonas aeruginosa PA14 wt strain as determined by whole-genome resequencing (Illumina MiSeq2x150bp PE, Nextera libraries). Isolates are coded with AA-BB-CC-: AA, antibiotic to which they are originally resistant; BB, antibiotic to which the clone shows collateral sensitivity; CC, well in the plate during experimental evolution.
Data Source 9 (separate file)
Source Data for Figure 4c and 4d. Estimated MIC values for several constructed mutants against carbenicillin and gentamicin.
